Pardes Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Carlsbad, calif., aug. 31, 2023 (globe newswire) -- pardes biosciences, inc. (nasdaq: prds) (pardes or the company) today announced that medipacific, inc. (medipacific), an affiliate of foresite capital, through its wholly owned subsidiary medipacific sub, inc. (merger sub), has successfully completed the previously announced tender offer to acquire all of pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the cash amount), plus (ii) a non-tradeable contingent value right (each, a cvr and each cvr together with the cash amount, the offer price) associated with any future monetization of its covid-19 antiviral portfolio and related intellectual property.

Larkspur, calif.--(business wire)-- #lifesciences--as previously announced, on july 16, 2023, medipacific sub, inc. (“purchaser”) and medipacific, inc. (“parent”), affiliates of foresite capital, entered into a definitive agreement and plan of merger (the “merger agreement”) with pardes biosciences, inc. (nasdaq: prds) (“pardes”) whereby purchaser agreed to acquire, subject to the terms of the merger agreement, pardes for a price per share in cash, plus a non-tradeable contingent value right (the “cvr”) associ.

Los angeles, ca / accesswire / august 19, 2023 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in pardes biosciences, inc. ("pardes" or "the company") (nasdaq:prds) for potential breaches of fiduciary duty on the part of its directors and management in connection with the company's agreement to be acquired by medipacific, inc. ("medipacific"). the investigation focuses on determining if the pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether medipacific is underpaying for the company.

Los angeles, ca / accesswire / august 18, 2023 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in pardes biosciences, inc. ("pardes" or "the company") (nasdaq:prds) for potential breaches of fiduciary duty on the part of its directors and management in connection with the company's agreement to be acquired by medipacific, inc. ("medipacific"). the investigation focuses on determining if the pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether medipacific is underpaying for the company.

Larkspur, calif.--(business wire)-- #lifesciences--as previously announced, on july 16, 2023, medipacific sub, inc. (“purchaser”) and medipacific, inc. (“parent”), affiliates of foresite capital, entered into a definitive agreement and plan of merger (the “merger agreement”) with pardes biosciences, inc. (nasdaq: prds) (“pardes”) whereby purchaser agreed to acquire, subject to the terms of the merger agreement, pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not mor.

Pardes Biosciences Inc.'s PRDS, -0.54% stock was up 12.4% in premarket trades Monday after the clinical-stage biopharmaceutical company said it agreed to be acquired by MediPacific Inc. for up to $2.19 a share. The purchase price is not less than $2.02 a share in cash and an additional cash amount of not more than 17 cents per share, with the final price per share being based on the amount of the company's net cash at closing, plus a non-tradeable contingent-value right associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

Pardes Biosciences, Inc. (PRDS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pardes Biosciences Seeking Strategic Alternatives. Pardes' Pipeline is depleted.

CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of COVID-19, announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 10:40 a.m. PT / 1:40 p.m. ET.

More short squeeze penny stocks to watch before February 2023. The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 8:00 a.m. GMT / 12:00 a.m. PT.

CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that management will participate in a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 7:30 a.m. PT / 10:30 a.m. ET in New York City.

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022 at 8:30 a.m. PT / 11:30 a.m. ET.

CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that it will give an oral presentation at the 35th International Conference On Antiviral Research (ICAR) 2022, to be held in Seattle and virtually from March 21-25 2022.

CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that Thomas G. Wiggans, Chief Executive Officer, and Uri A. Lopatin, M.D., Chief Scientific & Strategic Advisor, will present a company overview at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9, 2022 at 11:10 a.m. PT / 2:10 p.m. ET. The conference will take place virtually from March 7-9, 2022.